On November 9, 2021 MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs ("MAIA"), reported that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC) (Free SITC Whitepaper) which will be held November 10-14, 2021, in Washington, DC (Press release, MAIA Biotechnology, NOV 9, 2021, View Source [SID1234594946]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Title:

Telomerase-Driven Telomeric DNA Modification in Cancer Cells Leads to Efficient Induction of cGAS-mediated Innate and Adoptive Immune Responses

Abstract ID:

697

Category:

Immune-stimulants and immune modulators

Date:

Friday, Nov. 12, 2021

Time:

7:00 am – 8:30 pm

Location:

Poster Hall, Walter E. Washington Convention Center

Accepted abstracts can be found in the Journal for ImmunoTherapy of Cancer (JITC).